---
title: "Moleculin Biotech, Inc. (MBRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MBRX.US.md"
symbol: "MBRX.US"
name: "Moleculin Biotech, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T14:07:46.844Z"
locales:
  - [en](https://longbridge.com/en/quote/MBRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MBRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MBRX.US.md)
---

# Moleculin Biotech, Inc. (MBRX.US)

## Company Overview

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [moleculin.com](https://moleculin.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.26 | 103 | - | - | - |
| PB | 0.73 | 64 | 360.75 | 195.09 | 0.87 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **3**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 67% |
| Overweight | 1 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.08 |
| Highest Target | 31.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MBRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MBRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MBRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MBRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**